“…Myelosuppressive effect of the active variant (Arango, et al, 1999,Arango, et al, 2001,Gilmore, et al, 1999,Lord, et al, 1995 was investigated in several clinical trials of patients receiving chemotherapy (Bernstein, et al, 1997,Broxmeyer, et al, 1998,Clemons, et al, 1998,Marshall, et al, 1998. We previously showed that the recombinant MIP-1 variant, now called ECI301, strikingly enhanced the antitumor efficacy of subcutaneous tumor irradiation and induced an abscopal effect (Shiraishi, et al, 2008). Our study resulted in tumor-free mice with long-term survival without significant toxicity and complete rejection by surviving mice to a re-challenge with the same tumor cells.…”